Page 30 - Material Command News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail IMAGE: Study first author Nadia Koyratty is an epidemiology PhD candidate in the University at Buffalo School of Public Health and Health Professions. view more  Credit: University at Buffalo BUFFALO, N.Y. -- New research from the University at Buffalo suggests that breast cancer patients who drink sugar-sweetened beverages regularly are at increased risk for death from any cause and breast cancer in particular. Compared to women who never or rarely drank non-diet soda, those who reported drinking non-diet soda five times or more per week had a 62% higher likelihood of dyin...

B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb® Media Links Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients. MELSUNGEN, GERMANY and MONMOUTH JUNCTION, N.J., March 2, 2021 – B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation (NASDAQ: CTSO), a critical care...

CET- Comunicado - ";ultimaHoraHtml += " " + json.lead + "";}ultimaHoraHtml += ""; document.getElementById("urgente").innerHTML = ultimaHoraHtml; } } }); The CytoSorb adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream./ - CYTOSORBENTS B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI* Continuous Blood Purification Platform with CytoSorb*Joint marketing of CytoSorb* with B. Braun's newest OMNI* blood purification platform wil...

CytoSorbents to Present at the Cowen 41st Annual Health Care Conference News provided by Share this article MONMOUTH JUNCTION, N.J., Feb. 24, 2021 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces its participation the Cowen 41 st Annual Health Care Conference. Chief Executive Officer, Dr. Phillip Chan, MD, PhD will present a brief overview of the Company's progress and outlook follo...

/PRNewswire/ -- Medcura, Inc., a commercial-stage medical device company, announced today that it has been awarded a $2M follow-on grant to expand its...